Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
批准号:
10322442
负责人:
David Noel O'Dwyer
金额:
$24.9万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-01 至 2022-12-31
关键词:
AffectAnimal Disease ModelsAnimal ExperimentationAnimal ModelAnimalsAntibioticsAreaBacteriaBioinformaticsBiological Response ModifiersBleomycinBronchoalveolar Lavage FluidCellsCellular biologyCessation of lifeClinicalCommunitiesCulture-independent methodsDataDevelopmentDevelopment PlansDiseaseDisease ProgressionEcologyEtiologyFibrosisFirmicutesFunctional disorderFutureGene ExpressionGerm-FreeGnotobioticGoalsGram-Negative BacteriaHeterogeneityHost DefenseHumanImmuneImmunologyInflammationInflammatoryInnate Immune ResponseInternal MedicineInterstitial Lung DiseasesKnowledgeLaboratoriesLeadLigandsLungLung diseasesMeasuresMentorsMichiganMicrobeMicrobiologyModelingMusNational Heart, Lung, and Blood InstituteOrganOrganismOutcomePathogenesisPatientsPersonsPhasePhysiciansPlayPrevalenceProgressive DiseaseProteobacteriaPublishingPulmonary FibrosisPulmonologyReceptor ActivationReceptor CellReceptor SignalingRecommendationReportingResearchRoleScientistSeriesStrategic PlanningTLR2 geneTLR4 geneTechniquesTherapeuticToll-like receptorsTrainingUnited StatesUniversitiesWild Type Mousebasecareer developmentdefense responsedesigndysbiosisexperienceexperimental studyfibrogenesisglobal healthhost microbiomehost microbiotaidiopathic pulmonary fibrosisimprovedindium-bleomycinlung microbiotamedical schoolsmembermicrobialmicrobiomemicrobiotamortalitymouse toll-like receptor 2novelnovel therapeutic interventionrespiratoryrespiratory microbiomerespiratory microbiotaresponseskillswound healing
中文摘要
项目总结/摘要
肺纤维化中Toll样受体与呼吸道菌群的相互作用
特发性肺纤维化(IPF)是一种致死性疾病,目前尚无治愈方法,病因不明,
了解发病机制。这是一个新出现的全球健康问题,估计有500万人受到影响
全世界每年有17,000人死于美国。非培养型微生物的出现
鉴定技术已经鉴定了与几种肺部疾病相关的呼吸道微生物组。小说
使用IPF患者的支气管肺泡灌洗液(BAL)进行的临床观察支持了
呼吸道微生物组,包括社区成员的变化和疾病的总体负担(生态失调)
进展和死亡率。先天性免疫介质,包括Toll样受体(TLR)已报告
与IPF临床结局的相关性,突出了先前未被充分认识的宿主防御作用,
IPF发病机制。然而,呼吸道微生物组和宿主相互作用在肺部疾病中的确切作用,
对纤维化了解甚少。该项目的中心假设是,生态失调促进进行性肺
通过刺激TLR来调节细胞特异性纤维化反应,从而抑制纤维化。具体目标是
采用微生物生态学、生物信息学、细胞生物学和动物模型(包括细菌
自由和无菌模型),以确定生态失调在调节肺病理生理学中的作用,
纤维化长期目标是了解宿主-微生物群相互作用在IPF发病机制中的作用
并根据更好的理解为患者设计具体的治疗策略。为了
为达到这一目的,建立了无菌小鼠和常规小鼠肺纤维化动物模型
有或没有抗生素操纵的微生物群将进行初步研究,以了解的作用,
生态失调,宿主先天免疫和防御反应,并确定与
实验性肺纤维化以指导细菌学研究。随后的实验性纤维化研究,
缺乏与革兰氏阳性(Toll样受体2)识别相关的TLR的动物模型,
革兰氏阴性菌(Toll样受体4)将进一步定义微生物-宿主相互作用。奥德怀尔博士
在TLR信号传导和纤维化方面有丰富的经验,并曾在该领域发表过文章。他的职业发展
该计划的重点是在动物建模和微生物生态学的生物信息学方面的进一步指导培训。
该项目将在密歇根大学医学院内通过医学系进行,
内科,微生物学和免疫学系和大学的宿主微生物组倡议。
这些最先进的研究将确定与纤维化相关的候选微生物,
微生物群-宿主(TLR)相互作用驱动纤维化,并将突出生态失调发挥的关键作用
在肺纤维化的发病机制中,以推进我们对疾病病因学的认识,完善目前的动物模型,
为这种毁灭性的肺部疾病提供了新的治疗策略。
英文摘要
PROJECT SUMMARY/ABSTRACT
Toll-like receptor and respiratory microbiota interactions in pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a lethal disease with no known cure, unknown etiology and poorly
understood pathogenesis. It is an emerging global health issue with an estimated 5 million people affected
worldwide and 17,000 deaths in the United States annually. The advent of culture-independent microbial
identification techniques has identified a respiratory microbiome associated with several lung diseases. Novel
clinical observations using bronchoalveolar lavage (BAL) fluid from IPF patients support a role for the
respiratory microbiome, both changes in community members and overall burden (dysbiosis) in disease
progression and mortality. Innate immune mediators including Toll-like receptors (TLR) have reported
associations with clinical outcomes in IPF, highlighting the previously underappreciated role of host defense in
IPF pathogenesis. However, the precise role of the respiratory microbiome and host interaction in pulmonary
fibrosis is poorly understood. The central hypothesis of this project is that dysbiosis promotes progressive lung
fibrosis through stimulation of TLRs to modulate cell-specific fibrotic responses. The specific objective is to
employ techniques from microbial ecology, bioinformatics, cell biology and animal modeling (including germ
free and gnotobiotic models) to determine the role of dysbiosis in regulating lung pathophysiology in pulmonary
fibrosis. The long term goal is to understand the role of host-microbiota interactions in the pathogenesis of IPF
and design specific therapeutic strategies for patients based on an improved understanding. In order to
achieve this objective, established animal models of pulmonary fibrosis in germ free and conventional mice
with or without antibiotic manipulation of the microbiota will be studied initially to understand the role of
dysbiosis, the host innate immune and defense response and to identify microbes associated with
experimental pulmonary fibrosis to guide gnotobiotic studies. Subsequent studies of experimental fibrosis in
animal models deficient in TLRs associated with the recognition of Gram positive (Toll-like receptor 2) and
Gram negative bacteria (Toll-like receptor 4) will further define microbiota-host interactions. Dr. O’Dwyer has
experience in TLR signaling and fibrosis and has previously published in this area. His career development
plan is focused on further mentored training in animal modeling and the bioinformatics of microbial ecology.
This project will be undertaken within the University of Michigan’s Medical School through the Department of
Internal Medicine, Department of Microbiology and Immunology and the University’s Host Microbiome Initiative.
These state-of-the-art studies will identify candidate organisms associated with fibrosis, characterize
microbiota-host (TLR) interactions that drive fibrogenesis and will highlight the crucial role that dysbiosis plays
in the pathogenesis of lung fibrosis to advance our understanding of disease etiology, refine current animal
models and inform new therapeutic strategies for this devastating lung disorder.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.matbio.2018.04.003
发表时间:
2018-04
期刊:
Matrix biology : journal of the International Society for Matrix Biology
影响因子:
--
作者:
[D. O’Dwyer;S. Gurczynski;B. Moore]
通讯作者:
D. O’Dwyer;S. Gurczynski;B. Moore
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10414838
-
项目类别:
-
资助金额:$51.09万
-
财政年份:2022
-
负责人:David Noel O'Dwyer
-
依托单位:
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10684165
-
项目类别:
-
资助金额:$50.14万
-
财政年份:2022
-
负责人:David Noel O'Dwyer
-
依托单位:
Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis
-
批准号:10294291
-
项目类别:
-
资助金额:$47.7万
-
财政年份:2021
-
负责人:David Noel O'Dwyer
-
依托单位:
Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary
-
批准号:10080752
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2018
-
负责人:David Noel O'Dwyer
-
依托单位:
海外基金